Open company graph database — free web & API
Login

DAIICHI SANKYO BELGIUM N.V.-S.A.

Daiichi Sankyo Belgium N.V.-S.A.Alias第一三共ベルギーN.V.-S.A.Alias
Ticker
—
Listed market
—
Country
France
Employees (consolidated)
3,000
Related companies
0
§01

Basic information

BASIC
Head office
Alliance Business Park, Boulevard of France 3-5, 1420 Braine-l'Alleud, Belgium
Chief executive
Employees (non-consolidated)
3,000 people
Employees (consolidated)
3,000 people
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

7
Adverse Event ReportingHealthcare ServicesPharmaceutical Information ServicesAdverse event reportingPharmacovigilanceMedical inquiries handlingWebsite services and support
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§06

History

24 EVENTS

Our roots in Europe can be traced back to Luitpold-Werk, a pharmaceutical company founded on 22 January 1910 in Munich, Germany.Sources

The company moves several times before establishing its first factory on Munich’s Zielstattstrasse in 1928 – the same street where our European headquarters are located today. By this time, the number of employees has increased to more than 100.Sources

By 1942, the number of employees has risen to about 300, even though raw materials are hard to obtain and export is limited.Sources

In 1943, Munich is bombed, and the facilities on Zielstattstrasse are destroyed. Business activities continue as far as possible, with departments moving to ten temporary offices and laboratories across the city. The company decides to build new production facilities in Pfaffenhofen.Sources

At the end of the Second World War, business activities have to be halted for several weeks. In the 1950s and 1960s, Luitpold-Werk establishes new offices in Munich and new production facilities in Pfaffenhofen.Sources

From 1962 onwards, the Luitpold-Werk increases its international presence and establishes affiliates in Brazil, Spain, Switzerland, and Italy. A second production site is built in Altkirch, France.Sources

From 1981 to 1986, subsidiaries are established in the United States, Portugal, and the United Kingdom, further increasing Luitpold’s international presence.Sources

Sankyo establishes subsidiaries in New York and Düsseldorf, allowing overseas clinical trials and expanding its international operations.Sources

Sankyo acquires Luitpold-Werk, gaining a presence in Europe and Latin America.Sources

Luitpold-Werk is renamed as Sankyo Pharma.Sources

Sankyo launches olmesartan (Olmetec in Europe, Benicar in the US) and acquires Paris-based Laboratories Fornet to expand in the French market.Sources

Sankyo and Daiichi establish a joint holding company in Japan named Daiichi Sankyo Company, Limited. The European merger follows one year later.Sources

Daiichi Sankyo Europe is founded as the new European headquarters in Munich, integrating business activities in the UK and Germany.Sources

Daiichi Sankyo acquires U3 Pharma in Germany and the marketing rights for Evista (raloxifene), establishing growth in Europe.Sources

Efient (prasugrel), an antiplatelet agent, is launched in several European countries.Sources

Daiichi Sankyo opens new affiliates in Ireland and Turkey, and increases field force capacity by taking over sales representatives from Merck Serono in multiple countries, growing European employees from about 1,700 to nearly 2,500.Sources

Following the earthquake and tsunami in Japan, Daiichi Sankyo Europe offers support and launches 'Daiichi Sankyo Children Aid' to help Japanese children affected by the disaster.Sources

Daiichi Sankyo presents Hokusai-VTE, a phase 3 study of edoxaban, at the ESC congress in Amsterdam. Later, results from the ENGAGE AF-TIMI 48 study are announced.Sources

Daiichi Sankyo acquires Ambit Biosciences. A new Pharmaceutical Development building is inaugurated at the German plant in Pfaffenhofen, providing a state-of-the-art environment for 100 employees.Sources

Edoxaban, an oral factor Xa-inhibitor, is approved in the European Union and introduced in the first markets.Sources

Daiichi Sankyo concludes a Europe-wide commercial licensing agreement with Esperion for oral bempedoic acid and its fixed-dose combination with ezetimibe.Sources

Bempedoic acid and its fixed-dose combination with ezetimibe are approved in the European Union in April 2020, later introduced into the market in late 2020. The company also launches relief efforts across Europe in response to COVID-19.Sources

Conditional approval of Daiichi Sankyo's first oncological product in Europe in January 2021.Sources

In April 2023, Daiichi Sankyo welcomed its new Greek affiliate as part of its European family.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑